Aviva PLC trimmed its stake in CVS Health Corp (NYSE:CVS) by 3.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 631,824 shares of the pharmacy operator’s stock after selling 23,473 shares during the period. Aviva PLC’s holdings in CVS Health were worth $49,737,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. BTR Capital Management Inc. raised its position in shares of CVS Health by 1.0% in the 2nd quarter. BTR Capital Management Inc. now owns 139,618 shares of the pharmacy operator’s stock worth $8,984,000 after buying an additional 1,420 shares during the period. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of CVS Health in the 2nd quarter worth $191,000. Veritas Investment Management LLP raised its position in shares of CVS Health by 12.5% in the 2nd quarter. Veritas Investment Management LLP now owns 784,004 shares of the pharmacy operator’s stock worth $50,447,000 after buying an additional 87,115 shares during the period. Comerica Bank increased its holdings in CVS Health by 1.3% in the 2nd quarter. Comerica Bank now owns 529,017 shares of the pharmacy operator’s stock valued at $35,941,000 after purchasing an additional 6,913 shares in the last quarter. Finally, Dana Investment Advisors Inc. acquired a new stake in CVS Health in the 2nd quarter valued at $9,936,000. Institutional investors own 84.50% of the company’s stock.

Shares of CVS Health stock opened at $78.91 on Thursday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.44 and a quick ratio of 1.94. The stock has a market cap of $81.71 billion, a PE ratio of 13.37, a price-to-earnings-growth ratio of 1.14 and a beta of 0.98. CVS Health Corp has a 1-year low of $60.14 and a 1-year high of $83.88.

CVS Health (NYSE:CVS) last announced its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share for the quarter, beating the consensus estimate of $1.71 by $0.02. The company had revenue of $47.27 billion during the quarter, compared to the consensus estimate of $47.22 billion. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. The company’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the firm earned $1.50 earnings per share. On average, analysts predict that CVS Health Corp will post 7.03 EPS for the current fiscal year.

Several analysts recently issued reports on the company. Cantor Fitzgerald assumed coverage on CVS Health in a report on Monday, November 26th. They issued an “overweight” rating and a $96.00 price target for the company. ValuEngine upgraded CVS Health from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. Loop Capital set a $80.00 price target on CVS Health and gave the company a “hold” rating in a report on Wednesday, November 28th. Goldman Sachs Group reiterated a “neutral” rating and issued a $87.00 price target on shares of CVS Health in a report on Thursday, November 29th. Finally, Evercore ISI assumed coverage on CVS Health in a report on Wednesday, November 28th. They issued an “outperform” rating and a $89.00 price target for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $90.69.

In other news, EVP Troyen A. Brennan sold 14,229 shares of the firm’s stock in a transaction dated Wednesday, November 14th. The stock was sold at an average price of $82.00, for a total transaction of $1,166,778.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Eva C. Boratto sold 13,311 shares of the firm’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $77.16, for a total value of $1,027,076.76. Following the sale, the executive vice president now owns 55,162 shares of the company’s stock, valued at $4,256,299.92. The disclosure for this sale can be found here. Insiders have sold 74,233 shares of company stock valued at $5,932,565 over the last 90 days. Insiders own 0.53% of the company’s stock.

WARNING: “CVS Health Corp (CVS) Shares Sold by Aviva PLC” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/cvs-health-corp-cvs-shares-sold-by-aviva-plc/2663746.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Featured Story: Systematic Risk and Investors

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.